{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:50:12Z","timestamp":1793515812229,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"30","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zoll Cardiac Management Solutions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>In patients with de novo heart failure with reduced ejection fraction (HFrEF), improvement of left ventricular ejection fraction (LVEF) is expected to occur when started on guideline-recommended medical therapy. However, improvement may not be completed within 90 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with HFrEF and LVEF \u2264 35% prescribed a wearable cardioverter-defibrillator between 2017 and 2022 from 68 sites were enrolled, starting with a registry phase for 3 months and followed by a study phase up to 1 year. The primary endpoints were LVEF improvement &amp;gt; 35% between Days 90 and 180 following guideline-recommended medical therapy initiation and the percentage of target dose reached at Days 90 and 180.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 598 patients with de novo HFrEF [59 years (interquartile range 51\u201368), 27% female] entered the study phase. During the first 180 days, a significant increase in dosage of beta-blockers, renin\u2013angiotensin system inhibitors, and mineralocorticoid receptor antagonists was observed (P &amp;lt; .001). At Day 90, 46% [95% confidence interval (CI) 41%\u201350%] of study phase patients had LVEF improvement &amp;gt; 35%; 46% (95% CI 40%\u201352%) of those with persistently low LVEF at Day 90 had LVEF improvement &amp;gt; 35% by Day 180, increasing the total rate of improvement &amp;gt; 35% to 68% (95% CI 63%\u201372%). In 392 patients followed for 360 days, improvement &amp;gt; 35% was observed in 77% (95% CI 72%\u201381%) of the patients. Until Day 90, sustained ventricular tachyarrhythmias were observed in 24 wearable cardioverter-defibrillator carriers (1.8%). After 90 days, no sustained ventricular tachyarrhythmia occurred in wearable cardioverter-defibrillator carriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Continuous optimization of guideline-recommended medical therapy for at least 180 days in HFrEF is associated with additional LVEF improvement &amp;gt; 35%, allowing for better decision-making regarding preventive implantable cardioverter-defibrillator therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae334","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:34:15Z","timestamp":1715906055000},"page":"2771-2781","source":"Crossref","is-referenced-by-count":74,"title":["Therapy duration and improvement of ventricular function in\n                    <i>de novo<\/i>\n                    heart failure: the Heart Failure Optimization study"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7587-1124","authenticated-orcid":false,"given":"Christian","family":"Veltmann","sequence":"first","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Carl-Neuberg-Str. 1, 30625 Hannover , Germany"},{"name":"Heart Center Bremen, Electrophysiology Bremen , Senator-Wessling-Str. 1, 28277 Bremen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-6338","authenticated-orcid":false,"given":"David","family":"Duncker","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Carl-Neuberg-Str. 1, 30625 Hannover , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1372-3438","authenticated-orcid":false,"given":"Michael","family":"Doering","sequence":"additional","affiliation":[{"name":"Heart Center Leipzig, University of Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva","family":"Gummadi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CVI of Central Florida , Ocala, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Robertson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Trinity Medical, WNY , Buffalo, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wittlinger","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Asklepios Harzklinik Goslar , Goslar , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron J","family":"Colley","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jackson Heart Clinic , Jackson, MS , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Perings","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Katholisches Klinikum Luenen , Luenen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orvar","family":"Jonsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sanford Cardiovascular Institute , Sioux Falls, SD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-117X","authenticated-orcid":false,"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Carl-Neuberg-Str. 1, 30625 Hannover , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, HCA Florida Heart Institute , St. Petersburg, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9915-4429","authenticated-orcid":false,"given":"Lars S","family":"Maier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Regensburg , Regensburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"2024080915565326000_ehae334-B1","doi-asserted-by":"crossref","first-page":"e004512","DOI":"10.1161\/JAHA.116.004512","article-title":"Avoiding untimely implantable cardioverter\/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter\/defibrillator\u2014the PROLONG study","volume":"6","author":"Duncker","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2024080915565326000_ehae334-B2","doi-asserted-by":"crossref","first-page":"e006833","DOI":"10.1161\/CIRCHEARTFAILURE.119.006833","article-title":"Improvement in left ventricular ejection fraction in outpatients with heart failure with reduced ejection fraction: data from CHAMP-HF","volume":"13","author":"DeVore","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2024080915565326000_ehae334-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ehf2.13729","article-title":"Heart failure with recovered ejection fraction and the utility of defibrillator therapy: a review","volume":"9","author":"Devgun","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2024080915565326000_ehae334-B4","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2024080915565326000_ehae334-B5","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2024080915565326000_ehae334-B6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ehf2.14197","article-title":"A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Abdin","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2024080915565326000_ehae334-B7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.cardfail.2022.02.011","article-title":"Medical therapy during hospitalization for heart failure with reduced ejection fraction: the VICTORIA registry","volume":"28","author":"Greene","year":"2022","journal-title":"J Card Fail"},{"key":"2024080915565326000_ehae334-B8","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024080915565326000_ehae334-B9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2024080915565326000_ehae334-B10","doi-asserted-by":"crossref","first-page":"e004478","DOI":"10.1161\/CIRCHEARTFAILURE.117.004478","article-title":"Waiting period before implantable cardioverter-defibrillator implantation in newly diagnosed heart failure with reduced ejection fraction: a window of opportunity","volume":"10","author":"DeFilippis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2024080915565326000_ehae334-B11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024080915565326000_ehae334-B12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00399-022-00920-5","article-title":"The Heart Failure Optimization Study (HF-OPT): rationale and design","volume":"34","author":"Sanchez","year":"2023","journal-title":"Herzschrittmacherther Elektrophysiol"},{"key":"2024080915565326000_ehae334-B13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.tcm.2020.03.002","article-title":"Wearable cardioverter-defibrillators: a review of evidence and indications","volume":"31","author":"Cheung","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"2024080915565326000_ehae334-B14","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.115.015677","article-title":"Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II registry)","volume":"132","author":"Kutyifa","year":"2015","journal-title":"Circulation"},{"key":"2024080915565326000_ehae334-B15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.114.009924","article-title":"Evolution of left ventricular ejection fraction after acute myocardial infarction: implications for implantable cardioverter-defibrillator eligibility","volume":"130","author":"Sj\u00f6blom","year":"2014","journal-title":"Circulation"},{"key":"2024080915565326000_ehae334-B16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jchf.2018.05.004","article-title":"Heart failure with improved ejection fraction","volume":"6","author":"Gulati","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2024080915565326000_ehae334-B17","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1002\/ehf2.13630","article-title":"Characteristics and outcomes of heart failure with recovered left ventricular ejection fraction","volume":"8","author":"Zhang","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2024080915565326000_ehae334-B18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart failure with recovered left ventricular ejection fraction","volume":"76","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024080915565326000_ehae334-B19","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1093\/eurheartj\/ehz233","article-title":"Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study","volume":"40","author":"Ghimire","year":"2019","journal-title":"Eur Heart J"},{"key":"2024080915565326000_ehae334-B20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.121.054034","article-title":"Implantable cardioverter-defibrillator eligibility after initiation of sacubitril\/valsartan in chronic heart failure: insights from PROVE-HF","volume":"144","author":"Felker","year":"2021","journal-title":"Circulation"},{"key":"2024080915565326000_ehae334-B21","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3390\/s22052037","article-title":"Delayed improvement of left ventricular function in newly diagnosed heart failure depends on etiology\u2014a PROLONG-II substudy","volume":"22","author":"Mueller-Leisse","year":"2022","journal-title":"Sensors"},{"key":"2024080915565326000_ehae334-B22","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1002\/ehf2.13586","article-title":"Extended follow-up after wearable cardioverter-defibrillator period: the PROLONG-II study","volume":"8","author":"Mueller-Leisse","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2024080915565326000_ehae334-B23","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"2024080915565326000_ehae334-B24","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jacc.2017.10.053","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024080915565326000_ehae334-B25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(19)31996-8","article-title":"Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study","volume":"394","author":"Bauer","year":"2019","journal-title":"Lancet"},{"key":"2024080915565326000_ehae334-B26","doi-asserted-by":"crossref","first-page":"e222552","DOI":"10.1148\/radiol.222552","article-title":"Cardiac MRI to predict sudden cardiac death risk in dilated cardiomyopathy","volume":"307","author":"Li","year":"2023","journal-title":"Radiology"},{"key":"2024080915565326000_ehae334-B27","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.3390\/jcm10194409","article-title":"Contemporary pillars of heart failure with reduced ejection fraction medical therapy","volume":"10","author":"Rahamim","year":"2021","journal-title":"J Clin Med"},{"key":"2024080915565326000_ehae334-B28","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1093\/eurheartj\/ehac210","article-title":"Accelerated and personalized therapy for heart failure with reduced ejection fraction","volume":"43","author":"Shen","year":"2022","journal-title":"Eur Heart J"},{"key":"2024080915565326000_ehae334-B29","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2024080915565326000_ehae334-B30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2015.12.046","article-title":"Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation","volume":"67","author":"Roth","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024080915565326000_ehae334-B31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"Physicians\u2019 guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"21","author":"Komajda","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2024080915565326000_ehae334-B32","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/ejhf.1575","article-title":"Safety, tolerability and efficacy of rapid optimization, helped by NT-proBNP and GDF-15, of heart failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study","volume":"21","author":"Kimmoun","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2024080915565326000_ehae334-B33","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1056\/NEJMoa1211107","article-title":"Reduction in inappropriate therapy and mortality through ICD programming","volume":"367","author":"Moss","year":"2012","journal-title":"N Engl J Med"},{"key":"2024080915565326000_ehae334-B34","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa1609758","article-title":"Declining risk of sudden death in heart failure","volume":"377","author":"Shen","year":"2017","journal-title":"N Engl J Med"},{"key":"2024080915565326000_ehae334-B35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00392-020-01657-2","article-title":"Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry","volume":"110","author":"Veltmann","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2024080915565326000_ehae334-B36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/europace\/euaa268","article-title":"Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study","volume":"23","author":"Garcia","year":"2021","journal-title":"Europace"},{"key":"2024080915565326000_ehae334-B37","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/ehf2.13285","article-title":"Reverse remodelling by sacubitril\/valsartan predicts the prognosis in heart failure with reduced ejection fraction","volume":"8","author":"Moon","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2024080915565326000_ehae334-B38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ejhf.1501","article-title":"Major reduction in the risk of sudden cardiac death in patients with chronic heart failure with the use of drug and device combinations that favourably affect left ventricular structure","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/30\/2771\/58789554\/ehae334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/30\/2771\/58789554\/ehae334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T17:02:17Z","timestamp":1723222937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/30\/2771\/7691441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":38,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2024,6,12]]},"published-print":{"date-parts":[[2024,8,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae334","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,7]]},"published":{"date-parts":[[2024,6,12]]}}}